The U.S. military is moving forward with an unprecedented clinical initiative: administering MDMA-assisted therapy to active-duty soldiers grappling with post-traumatic stress disorder. Two federally funded studies expect to enroll roughly 186 service members next year in what would represent the first official investigation into psychedelic treatments within the armed forces.
The Department of Defense has allocated $4.9 million to each of two research sites: Walter Reed National Military Medical Center and Emory University working with the University of Texas Health Science Center. At Walter Reed alone, 91 military, National Guard, and reserve personnel suffering from PTSD will receive three separate MDMA doses spaced across a 10-month period. Participating soldiers will not face deployment during the study.
The funding authorization originated in the National Defence Authorization Act signed by then-President Joe Biden in December 2023, with Republican congressman Morgan Luttrell, a former Navy SEAL, championing the measure. Luttrell, who has personally undergone psychedelic therapy, framed the research as essential to military readiness. "Our men and women in uniform deserve every tool available to heal and stay in the fight," he stated at the time.
The push gained additional momentum in April when President Trump signed an executive order accelerating psychedelic research access, particularly for veterans. Trump highlighted the scope of the veteran suicide crisis: since 2001, more than 21 times as many veterans have died by suicide as have died in combat.
DoD and Veterans Affairs therapists are beginning formal training in psychedelic-assisted therapy to prepare for soldier enrollment. The deputy under secretary of war for personnel and readiness, Sean O'Keefe, is monitoring the research closely, according to January correspondence.
Rick Doblin, founding president of the Multidisciplinary Association for Psychedelic Studies (Maps), which has stewarded MDMA toward federal approval, sees the military trials as a natural extension of therapeutic work. "Helping people process trauma, whoever they are, is probably better than not," he said, dismissing moral reservations about treating active-duty personnel.
The rationale behind the approach stands somewhat counterintuitive: by helping soldiers process and metabolize trauma through guided MDMA sessions, the military hopes to reduce long-term disability and enable troops to remain effective. Military psychiatry has historically struggled with this challenge. During World War II, the Army administered barbiturates that induced deep sleep lasting up to 48 hours, allowing some soldiers to return to combat within days, though without addressing underlying trauma.
Yet critics have raised serious ethical concerns. Dennis McKenna, an ethnobotanist and author, warned that using psychedelics to restore combat capability, only to redeploy healed soldiers back to the front line, constitutes a form of exploitation. "It would be completely cynical and cruel of the government to throw them back into combat," he said. "It's an abuse of psychedelics to use them to reconstruct people so that they can become more efficient killing machines."
Doblin acknowledged a documented clinical risk: people treated with MDMA-assisted therapy show higher relapse rates when returning to stressful environments. The question of whether soldiers will be redeployed after completing the research remains unresolved.
Abroad, the landscape is shifting rapidly. In Ukraine, Maps has trained 55 therapists to conduct MDMA-assisted sessions for soldiers facing what leadership views as an existential conflict. Although MDMA therapy is not yet legal there, hundreds of Ukrainian troops have already undergone treatment with ketamine, a legal dissociative anesthetic, to address PTSD symptoms and return to combat.
Israel is launching its own large-scale psychedelic trial for trauma survivors. An MDMA-assisted group therapy study involving 168 participants, including military veterans and potentially active-duty soldiers affected by the October 7 Hamas attacks, is expected to begin dosing later this year. This would be Israel's largest psychedelic clinical trial to date. Psychologist Keren Tzarfaty, co-founder of Maps Israel and lead researcher, envisions the model as replicable globally for treating collective trauma.
Psychologist Rachel Yehuda, director of the Parsons Research Center for Psychedelic Healing at Icahn School of Medicine at Mount Sinai, noted that treating soldiers while trauma is ongoing presents a different clinical picture than treating veterans years after service ends. She also raised the possibility that MDMA-assisted therapy could prompt soldiers to question their military commitment or, conversely, strengthen their sense of mission.
Rick Doblin has proposed a more ambitious integration: incorporating MDMA-assisted therapy into basic training itself, administered as part of emotional conditioning alongside physical fitness. Such early intervention, he argues, could inoculate troops against developing PTSD after future combat exposure.
A persistent concern lingers over whether psychedelics might effectively suppress moral injury arising from war crimes or other ethically compromising actions. Doblin disputed this characterization, arguing that MDMA therapy typically heightens emotional sensitivity rather than numbing it. "A lot of times, people become more sensitive to the emotional consequences of what they did," he said, suggesting that untreated soldiers may pose greater operational risk.
The historical precedent casts a long shadow. From the late 1950s, the U.S. Army administered LSD to soldiers at a classified Maryland facility to explore whether the drug could incapacitate enemy personnel. One soldier dosed in 1958 later recounted the illusory nature of volunteering in a military context. "In the military, if you don't do something you will be ostracized," he told the New Yorker. "I believe they did give us the option to leave, at first, but you didn't really have a choice once you were in."
Author James Rodriguez: "The military is betting that healing trauma faster makes troops more deployable, but the ethics of that calculation deserve far more public scrutiny than they're getting."
Comments